PRESS RELEASES

Year
January 03 | 2023
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 08 | 2022
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
November 30 | 2022
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 17 | 2022
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
November 17 | 2022
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 10 | 2022
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
November 09 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
September 28 | 2022
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
August 31 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11 | 2022
RAPT Therapeutics Reports Second Quarter 2022 Financial Results